Human Haptocorrin in Hepatocellular Carcinoma

Authors:
  • SFSophie Fremont
    Sophie Fremont
  • CMColette Migeon
    Colette Migeon
  • FNFlorence Nodari
    Florence Nodari
  • SDSuzanne Droesch
    Suzanne Droesch
  • RPR.-Michel Parache
    R.-Michel Parache
  • JNJ.-Pierre Nicolas
    J.-Pierre Nicolas

Abstract
This study aimed to determine whether haptocorrin (HC), a vitamin B12 binder, is stored in hepatic cells and whether this storage is modified by hepatic carcinogenesis. It was carried out using immunohistochemistry on different liver tissues (normal liver and steatosis, N = 22; cirrhosis, N = 13; and hepatocellular carcinoma, N = 31). No significant immunostaining of HC was detected in noncancerous biopsies with the exception of in one case of cirrhosis. Hepatocellular carcinoma (HCC) sections showed a weak to moderate cytoplasmic staining of cancerous cells (93% of cases) and of noncancerous hepatocytes surrounding the tumor (95%) of cases. Sections with pseudoglandular structures showed a moderate to strong staining of their secretion products. These results and previous studies would seem to confirm the hypothesis that the raised HC serum level observed in HCC is due both to the increased hepatic synthesis of HC and to a decreased uptake by the liver of the particular isoform of this glycoprotein present in the serum of HCC patients.

This publication has 43 references indexed in Scilit: